LRP-1 Promotes Colon Cancer Cell Proliferation in 3D Collagen Matrices by Mediating DDR1 Endocytosis.
3D collagen matrix
DDR1
LRP-1
colon cancer cell
proliferation
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
02
2020
accepted:
04
05
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
Low density lipoprotein receptor related protein-1 (LRP-1) is a large ubiquitous endocytic receptor mediating the clearance of various molecules from the extracellular matrix. Several studies have shown that LRP-1 plays crucial roles during tumorigenesis functioning as a main signal pathway regulator, especially by interacting with other cell-surface receptors. Discoïdin Domain Receptors (DDRs), type I collagen receptors with tyrosine kinase activity, have previously been associated with tumor invasion and aggressiveness in diverse tumor environments. Here, we addressed whether it could exist functional interplays between LRP-1 and DDR1 to control colon carcinoma cell behavior in three-dimensional (3D) collagen matrices. We found that LRP-1 established tight molecular connections with DDR1 at the plasma membrane in colon cancer cells. In this tumor context, we provide evidence that LRP-1 regulates by endocytosis the cell surface levels of DDR1 expression. The LRP-1 mediated endocytosis of DDR1 increased cell proliferation by promoting cell cycle progression into S phase and decreasing apoptosis. In this study, we identified a new molecular way that controls the cell-surface expression of DDR1 and consequently the colon carcinoma cell proliferation and apoptosis and highlighted an additional mechanism by which LRP-1 carries out its sensor activity of the tumor microenvironment.
Identifiants
pubmed: 32582700
doi: 10.3389/fcell.2020.00412
pmc: PMC7283560
doi:
Types de publication
Journal Article
Langues
eng
Pagination
412Informations de copyright
Copyright © 2020 Le, Bennasroune, Collin, Hachet, Lehrter, Rioult, Dedieu, Morjani and Appert-Collin.
Références
Front Pharmacol. 2019 May 03;10:462
pubmed: 31130862
Breast Cancer Res Treat. 2015 Feb;150(1):9-18
pubmed: 25667101
Exp Cell Res. 2017 Aug 1;357(1):1-8
pubmed: 28408316
Oncogene. 2006 Sep 28;25(44):5994-6002
pubmed: 16652150
J Cell Sci. 2019 Jul 31;132(15):
pubmed: 31273033
J Biol Chem. 2004 Jul 23;279(30):31462-70
pubmed: 15136580
Pancreatology. 2019 Apr;19(3):429-435
pubmed: 30902418
Oncotarget. 2017 Aug 10;8(45):78614-78632
pubmed: 29108253
J Biol Chem. 2005 Dec 2;280(48):40187-94
pubmed: 16186104
Oncotarget. 2016 May 3;7(18):24908-27
pubmed: 27121132
J Biol Chem. 2003 May 9;278(19):16761-9
pubmed: 12611880
Mol Cell Biol. 2008 May;28(9):2980-95
pubmed: 18316405
Bio Protoc. 2018 Sep 5;8(17):
pubmed: 30263905
PLoS One. 2015 Jun 18;10(6):e0129994
pubmed: 26086247
Clin Cancer Res. 2008 Nov 15;14(22):7215-22
pubmed: 19010838
Pathobiology. 1997;65(4):195-203
pubmed: 9396043
J Mol Biol. 2009 Jan 16;385(2):432-45
pubmed: 19007791
Mol Cell. 1997 Dec;1(1):25-34
pubmed: 9659900
World J Gastroenterol. 2019 Jul 14;25(26):3408-3425
pubmed: 31341365
Pathol Biol (Paris). 2014 Apr;62(2):84-90
pubmed: 24661974
EMBO J. 2003 Mar 17;22(6):1289-301
pubmed: 12628922
Oncotarget. 2018 Jan 13;9(10):8849-8869
pubmed: 29507659
Front Mol Neurosci. 2017 Mar 01;10:54
pubmed: 28298885
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10026-31
pubmed: 10944199
Oncogene. 2012 Jan 26;31(4):480-93
pubmed: 21706048
Cancer Metastasis Rev. 2012 Jun;31(1-2):295-321
pubmed: 22366781
Mol Cell. 1997 Dec;1(1):13-23
pubmed: 9659899
Cell Adh Migr. 2018;12(4):335-347
pubmed: 29733741
PLoS One. 2010 Jul 14;5(7):e11584
pubmed: 20644732
Oncol Rep. 2007 May;17(5):1101-7
pubmed: 17390051
PLoS One. 2013;8(3):e59689
pubmed: 23555746
Mol Cell Biol. 2012 Aug;32(16):3293-307
pubmed: 22711991
Tumour Biol. 2016 Sep;37(9):12049-12059
pubmed: 27179963
Annu Rev Cell Dev Biol. 2011;27:265-90
pubmed: 21568710
PLoS Genet. 2015 May 19;11(5):e1005249
pubmed: 25992553
Front Pharmacol. 2015 Nov 10;6:271
pubmed: 26617523
J Biol Chem. 2013 Nov 22;288(47):34009-18
pubmed: 24129569
Nat Commun. 2017 Nov 17;8(1):1571
pubmed: 29146996
J Biol Chem. 2010 May 7;285(19):14308-17
pubmed: 20220145
Histopathology. 2011 Sep;59(3):567-71
pubmed: 22034896
PLoS One. 2015 Mar 16;10(3):e0116006
pubmed: 25774665
J Biol Chem. 2011 May 20;286(20):17672-81
pubmed: 21398698
Nanoscale. 2016 Apr 7;8(13):7144-54
pubmed: 26965453
EMBO Mol Med. 2018 Apr;10(4):
pubmed: 29438985
Front Pharmacol. 2016 Mar 14;7:55
pubmed: 27014069
Cancer Res. 2004 Oct 1;64(19):6973-7
pubmed: 15466189
J Am Soc Nephrol. 2019 Sep;30(9):1605-1624
pubmed: 31383731
Cell Adh Migr. 2017 Jul 4;11(4):316-326
pubmed: 27463962
Cell. 2016 Jun 30;166(1):47-62
pubmed: 27368100
FASEB J. 2019 Mar;33(3):3465-3480
pubmed: 30458112
J Biol Chem. 2001 Oct 19;276(42):39484-91
pubmed: 11507091
Oncotarget. 2015 Jun 30;6(18):16084-105
pubmed: 25840417
Int J Cardiol. 2014 Oct 20;176(3):805-14
pubmed: 25131918
Int J Biochem Cell Biol. 2014 Aug;53:15-23
pubmed: 24796846
J Biol Chem. 2007 Aug 17;282(33):24471-6
pubmed: 17553787
Oncol Rep. 2007 Feb;17(2):361-7
pubmed: 17203175
J Cell Sci. 2010 Oct 1;123(Pt 19):3336-46
pubmed: 20826454
J Biol Chem. 2009 Dec 4;284(49):34045-53
pubmed: 19815552
Mol Oncol. 2019 Sep;13(9):1855-1873
pubmed: 31116512